Immune checkpoint inhibitor therapy for treatment of periocular Merkel cell carcinoma: A systematic review of clinical outcomes and safety.

Thus, this study summarizes and evaluates the effectiveness and safety of ICIs for periocular merkel cell carcinoma.

Non-human studies, non-periocular merkel cell carcinoma, and reports without immune checkpoint inhibitor treatment were excluded.

Extracted data included patient demographics, tumor characteristics, treatment regimen, and patient outcomes.

Treatment regimens consisted of pembrolizumab (n = 6) and avelumab (n = 3), or both medications (n = 1).